modelCimetidine
Extends from Pharmacolibrary.Drugs.ATC.A.A02BA01.
Information
| name: | Cimetidine | |
| ATC code: | A02BA01 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 0.7 | L |
| clearance: | 250 | ml/min |
| other parameters in model implementation | ||
Cimetidine is a histamine H2 receptor antagonist used to reduce stomach acid production. It is indicated for the treatment and prevention of peptic ulcers, gastroesophageal reflux disease (GERD), and conditions of excessive gastric acid secretion such as Zollinger-Ellison syndrome. Cimetidine is widely approved and has been used in clinical practice for several decades, though newer H2 antagonists and proton pump inhibitors have largely replaced it.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers after a single oral dose.
References
Scheen, AJ (1996). Clinical pharmacokinetics of metformin. Clinical pharmacokinetics 30(5) 359–371. DOI:10.2165/00003088-199630050-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8743335
Zhang, YF, et al., & Zhong, DF (2016). Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers. Drug design, development and therapy 10 357–370. DOI:10.2147/DDDT.S95934 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26855561
Ochs, HR, et al., & Shader, RI (1987). Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clinical pharmacology and therapeutics 41(5) 562–570. DOI:10.1038/clpt.1987.72 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2882883
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)